Transaction Overview - Blade Passenger division 将以高达 1.25 亿美元的价格出售给 Joby Aviation[9]，这笔交易的价格可能会以现金或 Joby 股票支付[10] - Blade 的医疗部门将保留公开上市资格，并更名为 Strata Critical Medical ("Strata")，成为一家纯粹的合同医疗业务公司[9] - 预计资产剥离在调整后的 EBITDA 和自由现金流方面将保持中性，并得到约 700 万美元的年度企业成本效率的支持[9] Financial Performance (Q2 2025) - Medical 部门收入同比增长 18%[18] - Passenger 部门收入同比下降 13%[13] - Medical 部门调整后的 EBITDA 利润率为 13.4%，同比下降 1 个百分点[18] - Passenger 部门调整后的 EBITDA 同比增长 160 万美元[18] - 短途收入（不包括加拿大）同比下降 6%[18] Medical Segment Growth Drivers - 2018 年至 2024 年，心脏、肝脏和肺移植距离增加了 64%[38] - Blade 在器官移植航空物流领域的市场份额估计约为 30%[40] - 地面运输的总潜在市场为 2 亿美元[46] - 器官配置服务的总潜在市场约为 2.5 亿美元[53] Trinity Air Medical Acquisition Impact - 截至 2024 年 9 月 30 日的 12 个月内，Blade/Trinity Medical 部门的总收入约为 1.42 亿美元，分部调整后的 EBITDA 为 1630 万美元[62]

Core Insights - Blade Air Mobility, Inc. reported a 4.2% increase in revenue to $70.8 million for Q2 2025 compared to $67.9 million in Q2 2024, driven primarily by growth in the Medical segment [9][12] - The company announced the sale of its Passenger division to Joby Aviation for up to $125 million, while the Medical division will remain a standalone public company, rebranding as Strata Critical Medical [6][8] - Net loss improved significantly by $7.6 million year-over-year to $(3.7) million in Q2 2025, with Adjusted EBITDA increasing by $2.2 million to $3.2 million [6][14] Financial Results - Total revenue for the six months ended June 30, 2025, was $125.1 million, up 4.7% from $119.5 million in the same period of 2024 [3][9] - Cost of revenue increased by 2.9% to $53.1 million in Q2 2025, while total operating expenses decreased by 5.4% to $75.8 million [3][9] - Gross profit rose to $12.9 million in Q2 2025, reflecting a gross margin improvement to 18.2% from 16.7% in Q2 2024 [3][9] Segment Performance - Medical revenue increased by 17.6% year-over-year to $45.1 million in Q2 2025, while Passenger segment revenue decreased by 13.2% to $25.7 million [9][35] - Flight profit for the Medical segment was $9.9 million, with a flight margin of 22.0%, while the Passenger segment achieved a flight profit of $7.8 million and a flight margin of 30.5% [39][40] - The company reported a decrease in Short Distance revenue by 17.8% to $17.2 million, attributed to reduced demand following a helicopter incident and inclement weather [9][14] Strategic Updates - The divestiture of the Passenger division is expected to be neutral to Adjusted EBITDA and Free Cash Flow on a go-forward basis, supported by estimated corporate cost efficiencies of approximately $7 million [9][12] - Blade's Medical division will focus on contractual healthcare solutions with no direct reimbursement risk, aiming for a strong growth profile [8][9] - The company ended Q2 2025 with $113.4 million in cash and short-term investments, positioning itself for future growth and strategic investments [14][12]

Acquisition and Business Strategy - Joby Aviation is acquiring Blade Air Mobility for $125 million, aiming to expand its electric air taxi service [1] - The acquisition provides Joby with an existing customer base and more takeoff and landing locations [2] - Blade transported over 50,000 passengers in the NYC area last year, indicating a strong demand for helicopter shuttle services [3] Technology and Innovation - Joby's electric aircraft aims for zero operating emissions and reduced noise compared to traditional helicopters [7] - Joby plans to progressively introduce automation, with the long-term goal of pilot-free aircraft [8][9] - The electric helicopter technology has been in development for several years, with ongoing testing for safety and reliability [11] Regulatory and Public Perception - New York City Council passed a bill to restrict non-essential helicopter flights based on FAA noise standards [6] - Public concerns exist regarding helicopter noise, emissions, and safety risks, particularly in urban areas like New York City [4][5] - Joby emphasizes that its electric aircraft will lead to quieter skies, addressing community concerns [7]

Core Viewpoint - Blade Air Mobility, Inc. has announced the sale of its passenger division to Joby Aviation for up to $125 million, allowing Blade to focus on its medical logistics business, which will rebrand as Strata Critical Medical [1][9][10]. Company Overview - Blade Air Mobility provides air transportation and logistics, primarily for hospitals in the U.S., and is one of the largest transporters of human organs for transplant [12]. - Joby Aviation is developing an all-electric vertical take-off and landing air taxi service, intending to operate and sell its aircraft globally [14]. Transaction Details - The sale price for the passenger division is up to $125 million, which may be paid in cash or Joby stock, including up to $35 million in performance-based earnouts [10]. - The transaction is expected to close in the coming weeks, with a new ticker for Strata to be announced later [11]. Strategic Focus Post-Transaction - Following the divestiture, Strata will concentrate on its medical logistics and services, leveraging its asset-light platform to enhance its offerings and pursue growth through acquisitions [2][8]. - The medical division represented approximately 84% of Blade's Segment Adjusted EBITDA and 59% of its revenue in 2024, indicating a strong focus on this profitable segment [8]. Leadership Changes - Rob Wiesenthal, the current CEO of Blade, will join Joby as CEO of Blade Air Mobility and serve as Chairman of Strata [5]. - Will Heyburn and Melissa Tomkiel will become Co-CEOs of Strata while retaining their existing roles [6]. Partnership and Future Opportunities - A long-term partnership between Joby and Strata will provide access to Joby aircraft for medical use, enhancing Strata's service capabilities [4][9]. - The expected operational efficiencies from the divestiture are estimated at approximately $7 million annually, making the financial impact neutral in terms of Adjusted EBITDA and Free Cash Flow [5][9].

Company Overview - Blade Air Mobility, Inc. is a provider of air transportation and logistics services, primarily for hospitals and passengers in the United States and Southern Europe [3] - The company is one of the largest transporters of human organs for transplant and offers helicopter and fixed-wing services [3] - Blade operates an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies, facilitating a transition to Electric Vertical Aircraft (EVA or eVTOL) for lower-cost, quiet, and emission-free air mobility [3] Upcoming Financial Results - Blade will release its financial results for the second quarter ended June 30, 2025, on August 5, 2025, before the market opens [1] - A conference call will be held on the same day at 8:00 am Eastern Time, hosted by the CEO and CFO, including a question-and-answer session [1][2]

Group 1: LATAM Airlines Group S.A. (LTM) - LATAM Airlines Group S.A. is a passenger and cargo air transportation services company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for LATAM's current year earnings has increased by 22.3% over the last 60 days [1] - LATAM has a PEG ratio of 0.62, which is lower than the industry average of 0.64, and possesses a Growth Score of A [1] Group 2: Unisys Corporation (UIS) - Unisys Corporation is an information technology solutions company with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for Unisys's current year earnings has increased by 132% over the last 60 days [2] - Unisys has a PEG ratio of 0.51, significantly lower than the industry average of 2.84, and possesses a Growth Score of B [2] Group 3: Great Lakes Dredge & Dock Corporation (GLDD) - Great Lakes Dredge & Dock Corporation is a dredging services company with a Zacks Rank 1 [3] - The Zacks Consensus Estimate for Great Lakes Dredge & Dock's current year earnings has increased by 39.1% over the last 60 days [3] - Great Lakes Dredge & Dock has a PEG ratio of 1.00, compared to the industry average of 6.87, and possesses a Growth Score of A [3]

Blade Air Mobility (BLDE) Conference Summary Company Overview - Blade Air Mobility has been operational for eleven years, initially focusing on helicopter passenger transport in New York and expanding to European markets such as Monaco, Nice, Cannes, and Geneva [1][2] - The company aims to transition from helicopters to electric vertical takeoff and landing (eVTOL) aircraft, leveraging an asset-light model that allows for future aircraft swaps [2][4] Industry Dynamics - The transition to eVTOL is expected to occur soon, with potential commercialization timelines for manufacturers like Adobe and Archer projected for late 2025 to early 2026 in the Middle East and late 2027 to early 2028 in the U.S. [10][11] - Blade is well-positioned to capitalize on this transition due to its established infrastructure and technology stack, which includes heliports in key markets [12][14] Key Business Segments Passenger Transport - Blade has successfully penetrated the passenger market, offering competitive pricing that has attracted a significant customer base [11] - The company has broken through pricing barriers, offering a $95 annual airport pass for frequent flyers [11] Medical Transport - Blade is the largest air transporter of human organs in the U.S., with a business generating approximately $150 million, surpassing its passenger transport revenue [5][6][37] - The medical segment is expected to grow in double digits, with a target margin expansion from 15% to high teens due to increased control over owned jets [34][35] - Blade holds about 30-35% of the organ transport market, indicating significant growth potential [37] Technological Advancements - The company is exploring the integration of AI in operations, aiming for enhanced safety and efficiency in future eVTOL aircraft [21][22] - Blade does not manufacture its own aircraft but collaborates with established manufacturers like Bell and Airbus [23] Financial Performance - Blade is ahead of its profitability projections, with adjusted EBITDA expected to exceed $10 million in 2025, up from just over $1 million last year [43][45] - The company maintains a strong financial position with $120 million in cash and zero debt, focusing on strategic acquisitions in the medical sector [40][42] Strategic Initiatives - Blade is actively seeking acquisitions that can enhance its medical transport capabilities and leverage existing hospital relationships [40][42] - The company is involved in various high-profile events to increase brand recognition and attract new customers, such as the Ryder Cup and major music festivals [28][29] Conclusion - Blade Air Mobility is strategically positioned to lead the transition to eVTOL aircraft while maintaining a strong foothold in the medical transport sector, showcasing impressive financial growth and operational efficiency [43][45]

Summary of Blade's Conference Call Company Overview - Blade operates in two primary segments: Medical (60% of revenue) and Passenger (40% of revenue) [4][5] - The Medical segment is a leading transporter of human organs for transplant in the U.S., generating approximately $150 million in revenue with a 13% EBITDA margin over the last twelve months [5][6] - The Passenger segment focuses on short-distance transportation in the U.S. and Europe, generating about $6.3 million in adjusted EBITDA [8] Key Growth Drivers Medical Segment - The industry growth rate is in the high single digits, driven by technology adoption and regulatory changes [6][13] - Blade has a 30% market share in air logistics, with ongoing customer acquisition, including two new high-volume transplant centers [14][15] - Ancillary services, such as ground logistics and organ placement services, are growing at or above the overall growth rate [15] - The company aims for a 15% EBITDA margin in the Medical segment, with expectations of improvement in the second half of the year [17][19] Passenger Segment - The transition to electric vertical takeoff and landing (eVTOL) aircraft is seen as a significant growth opportunity, with new landing zones viewed as new business opportunities [33][45] - The company has restructured its European operations and exited the Canadian market, leading to improved profitability [30][31] - Blade anticipates low single-digit growth in the passenger business for the year, excluding Canada [34] Technology and Operations - Blade employs a technology platform in the Medical segment for real-time logistics management and data analytics [21] - The Passenger segment has a consumer-facing app and operational technology for flight management [36][38] - The company operates an asset-light model in the Passenger segment, relying on third-party aircraft to mitigate economic sensitivity and seasonality [39] Market Trends and Competitive Landscape - The company has observed a seasonal pickup in demand for the Passenger segment as summer approaches, despite some softness in New York-centric products [41] - Blade's established brand, scale, and infrastructure position it well against competitors entering the eVTOL market [49][56] - The introduction of eVTOLs is expected to create new landing zones and expand market opportunities [54][62] Capital Allocation Strategy - Blade has $120 million in cash with no debt, focusing on strategic acquisitions in the Medical segment and investments in additional aircraft and vehicles [64] - The company views its medical business as a logistics platform with potential for expansion into other time-critical logistics markets [65] Investment Thesis - Blade is at an inflection point, transitioning from breakeven EBITDA to generating positive cash flow [67] - There is significant growth potential in the Medical segment, with a target of high teens EBITDA margins, and attractive optionality in the Passenger segment ahead of the eVTOL transition [68]

Financial Data and Key Metrics Changes - The company reported an 11% revenue growth excluding Canada, with a year-over-year improvement in adjusted EBITDA of $2.3 million [7][9] - Adjusted EBITDA for the passenger segment improved by $2.7 million year-over-year, reaching $6.3 million as of Q1 2025, up from $3.6 million in Q4 2024 [9][16] - Medical revenue remained roughly flat year-over-year at $35.9 million, with significant variability in monthly growth trends [17][20] Business Line Data and Key Metrics Changes - Passenger segment revenue grew by 42% year-over-year excluding Canada, marking the first adjusted EBITDA profitable quarter since going public [7][9] - Short distance revenue increased by 28.1% year-over-year, primarily driven by growth in Europe [16] - Jet and Other revenue increased by 60% year-over-year due to higher flight volume and revenue per flight [16] Market Data and Key Metrics Changes - The European market showed strong revenue growth attributed to restructuring efforts, which improved operational efficiency and customer experience [8][16] - The medical business is expected to benefit from strong underlying transplant volume growth, with industry transplant volume rising 7% year-over-year [24] Company Strategy and Development Direction - The company is focused on disciplined capital allocation, evaluating investments in aircraft and medical acquisitions to strengthen its competitive position [14][45] - The transition from helicopters to eVTOL is seen as a key strategic direction, with expectations for deployment in late 2025 to early 2026 [62] - The company aims to enhance profitability through cost rationalization initiatives and restructuring efforts, particularly in the passenger segment [10][13] Management's Comments on Operating Environment and Future Outlook - Management acknowledged economic uncertainty but expressed confidence in the resilience of their higher-end consumer base and ongoing demand in leisure markets [12][32] - The company expects continued revenue growth in the medical segment, with double-digit growth anticipated for the year [24][25] - Management noted that maintenance downtime is expected to moderate in the second half of 2025, leading to improved adjusted EBITDA margins [20][25] Other Important Information - The company ended the quarter with no debt and $120 million in cash and short-term investments, providing flexibility for strategic investments [23] - The company has implemented a withhold to cover method for taxes on employee stock-based compensation, effectively reducing outstanding shares [22] Q&A Session Summary Question: Themes for the year regarding passenger and medical segments - Management highlighted improved profitability in the passenger segment and the impact of maintenance on medical revenue, with expectations for better performance in the second half of the year [28][30] Question: Revenue contribution from Europe and sustainability of growth - Management confirmed approximately $6 million of revenue from Europe in Q1, attributing growth to restructuring and improved service [44] Question: Capital allocation priorities - The company is focused on tactical and strategic medical acquisitions, organic growth initiatives, and has a buyback authorization in place [45][46] Question: Bookings trends and impact of recent issues - Management noted that bookings for summer appear better than last year, but emphasized the on-demand nature of their service [50][53] Question: Repositioning aircraft strategy - Management explained that repositioning will always be part of the business, with a low to mid single-digit revenue headwind expected [71][72] Question: Impact of economic conditions on aircraft acquisitions - Management stated that there is no impact on their aircraft acquisition strategy, with plans to add a low single-digit number of aircraft over the next year or two [75][76]

Financial Highlights - FY 2024 revenue reached $249 million, showing a year-over-year growth of 10%[6] - Medical revenue for FY 2024 was $147 million, with a year-over-year growth of 16%[6] - Adjusted EBITDA improved by $178 million year-over-year in FY 2024[6] - Q1 2025 revenue was $54 million, reflecting a 10% year-over-year growth excluding Canada[6] - Passenger revenue in Q1 2025 was $18 million, showing a 42% year-over-year increase excluding Canada[6] - Adjusted EBITDA improved by $23 million year-over-year in Q1 2025[6] Medical Segment - Medical segment revenue for the trailing twelve months ending March 31, 2025, was $147 million, an 8% year-over-year growth[11] - Medical segment adjusted EBITDA for the same period was $19 million, with a 25% year-over-year growth[11] - Flight Profit for the medical segment was $33 million, with a 22% margin and 25% year-over-year growth[11] Passenger Segment - Passenger segment revenue for the trailing twelve months ending March 31, 2025, was $105 million, a 10% year-over-year growth, or 42% excluding Canada[11] - Passenger segment adjusted EBITDA for the same period was $63 million, with a $109 million growth year-over-year[11] - Flight Profit for the passenger segment was $28 million, with a 27% margin and 48% year-over-year growth[11] Organ Transplant - From 2018 to 2024, heart, liver, and lung transplant distances increased by 64%[42] Ground Transport - Blade Medical's ground transport annualized revenue is approximately $20 million[50]